"The Three Graces" Marble statue of three women by Canova

Why Women's Intimate Health Can't Wait: A Letter From Our CEO

By Dr Marco Morelli, Chief Executive Officer, BiotaLife Healthcare

Dr Marco Morelli, Chief Executive Officer, BiotaLife Healthcare

For too long, women have been told to put up with it.

Put up with the itching that comes back weeks after the cream runs out. With symptoms that return after every course of antibiotics. With burning from products that were meant to help. With being told it is common, as if common meant acceptable.

It is common. Recurrent thrush alone affects an estimated 138 million women worldwide every year¹. And 80% of women who give birth vaginally experience perineal trauma, representing roughly 450,000 women each year in the UK alone².

Yet, the way we manage women’s intimate health has barely moved in decades. That is the problem BiotaLife exists to solve, and it is why I believe we cannot afford to move slowly.

From managing symptoms to restoring balance

Most of today's options are built to manage symptoms. Antibiotics and antifungals clear the immediate problem, but they act indiscriminately, reducing the protective Lactobacillus bacteria that keep the vaginal environment in balance. Acid-based gels aim to correct pH, but independent laboratory research has found that many can damage the vaginal lining and trigger inflammation³. Heavy, uncomfortable oils or balms used for intimate care provide short-term soothing at the price of long-term risk during and after pregnancy. For many women, the result is a cycle: relief, recurrence, repeat. Even worse, products designed to support women can unknowingly disrupt the delicate intimate balance, leading to unnecessary pain and discomfort.

The next generation of women's health solutions must move beyond this. They must be designed to restore and protect the body's own balance, not override it. Science-backed, microbiome-first, and designed for real life.

That conviction shapes everything we do.

Our mission is to develop science-backed, microbiome-first solutions designed to relieve discomfort and address intimate health conditions by restoring and protecting the body’s own balance, and to educate, because women’s health has been overlooked and underfunded for far too long.

Our vision is a future where intimate care actually works, supporting a woman’s body, not fighting it, at every stage of her life, and where every woman has the knowledge to understand and care for her own intimate health.


The science exists

I have spent more than a decade driving innovation across healthtech and medical device development, bringing breakthrough technologies from initial concept to market. That work teaches you one thing above all: in healthcare, evidence is not a marketing asset. It is the price of entry.

So, I am not asking anyone to take our vision on trust. It is built on research and proven evidence. In laboratory work at King's College London led by Prof Paul Long, our CTO, our hydrogel supported the regrowth of protective Lactobacilli to levels expected in a healthy vagina, using swabs from women with diagnosed bacterial vaginosis (BV) and thrush. In BV samples, it supported significantly more lactobacilli than the market-leading acid-based gels⁴. This research is the foundation of DuoBalance™.

Similarly, a recent laboratory study led by Prof. Catherine Tuleu at UCL demonstrated that leading intimate health moisturisers disrupt the local microbiome of the perineum and vulva⁵. This increases the risk of tearing, soreness, and dryness, particularly during pregnancy and postpartum. To address this, we developed BloomCalma™ and why we tested it for compatibility with protective lactobacilli.

We work in partnership with King's College London, UCL and UCL Ventures, and our Scientific Advisory Board brings clinical and pharmaceutical expertise from the University of Oxford and UCL. Our clinical validation is conducted in collaboration with NHS Oxford and NHS Leeds. Science of this calibre deserves to reach women, not sit in a journal.

The need is urgent

Women's health remains one of the most under-invested areas in healthcare, and intimate health sits at the very edge of it. Meanwhile, antimicrobial resistance is a growing global threat. Every course of antibiotics or antifungals taken for a condition that keeps coming back adds to that pressure. A model that depends on ever stronger antimicrobials is not one we can keep relying on.

Why the window is now

Three things have changed. Microbiome science has matured from theory into something we can design products around. Women are better informed than ever and are asking harder questions about what they put on and in their bodies. And the case for antimicrobial-first care is getting harder to make.

The science exists, the need is urgent, and the window for bold, evidence-led innovation is now. If we wait for someone else to act, women wait too.

How we are building it

Urgency does not mean cutting corners. It means moving fast on everything we control, from partnerships to manufacturing to getting products into women's hands, and never compromising on evidence.

We are building in two steps. This November we launch BloomCalma™, a pH-balanced microbiome-friendly intimate moisturising gel for external use during pregnancy and postpartum, for external use, designed for perineal massage and intimate comfort. In parallel, DuoBalance™, our patented, antibiotic-free and acid-free candidate medical device designed to treat BV and thrush, is now advancing into clinical trials.

Each step is designed to earn women's trust, and to keep it.

Women have waited long enough for intimate care that works with their bodies. At BiotaLife, we’re ending the wait.


References

  1. Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. The Lancet Infectious Diseases 2018;18(11):e339-e347. https://doi.org/10.1016/S1473-3099(18)30103-8
  2. Hodgetts Morton V, Man R, Perry R, et al. Childbirth Acquired Perineal Trauma study (CHAPTER): a UK prospective cohort study protocol. BMJ Open 2024;14:e086724. https://doi.org/10.1136/bmjopen-2024-086724
  3. Tyssen D, Hearps AC, Guntur K, et al. The impact of over-the-counter lactic acid containing vaginal gels on the integrity and inflammatory state of the vaginal epithelium in vitro. Frontiers in Reproductive Health 2022;4:915948. https://doi.org/10.3389/frph.2022.915948
  4. Long PF. A new paradigm for treating refractory and recurrent infectious vaginal discharge. JAC-Antimicrobial Resistance 2025 Jul;7(Suppl 3):dlaf118.017. https://doi.org/10.1093/jacamr/dlaf118.017
  5. Tuleu C, et al. Does What We Put on the Vulva and Perineum Matter ? - Microbiome Compatibility of Women’s Intimate Care Products. British Journal of Midwifery 2026 [submitted for publication] 



FAQ

What is BiotaLife Healthcare's mission?
BiotaLife Healthcare’s mission is to develop science-backed, microbiome-first solutions designed to relieve discomfort and address intimate health conditions by restoring and protecting the body’s own balance, and to educate, because women’s health has been overlooked and underfunded for far too long. Rather than relying solely on treatments that clear bacteria indiscriminately, BiotaLife designs solutions that support the body’s own protective microbiome.

What is BiotaLife's vision?
BiotaLife’s vision is a future where intimate care actually works, supporting a woman’s body, not fighting it, at every stage of her life, and where every woman has the knowledge to understand and care for her own intimate health. From pregnancy and postpartum to conditions that affect women throughout adulthood, BiotaLife aims to make microbiome-first care the standard rather than the exception.

Who is Dr Marco Morelli?
Dr Marco Morelli is Chief Executive Officer (CEO) of BiotaLife Healthcare. He has more than 10 years of company management experience in healthtech and medical device development, and holds a PhD in Applied Physics and an Executive MBA. He leads BiotaLife's strategy to bring evidence-led, microbiome-first care to women.

Why does BiotaLife focus on women's intimate health?
Intimate health conditions such as BV and thrush are extremely common and often recur, yet treatment approaches have changed little in decades. Women's health is also one of the most under-invested areas in healthcare. BiotaLife sees a clear, urgent need for evidence-led solutions designed around the women’s microbiome.

Who are BiotaLife's research partners?
BiotaLife Healthcare works in partnership with King's College London, UCL and UCL Ventures. Its research is led by Prof Paul Long, CTO at BiotaLife and Professor of Pharmacognosy and Microbiologyat King's College London, and supported by a Scientific Advisory Board composed by Prof Sally Collins (Professor of Obstetrics at University of Oxford), Prof Catherine Tuleu (Professor of Paediatric Pharmaceutics at UCL) and Dr Smita Salunke (Senior Research Fellow in Pharmaceutics at UCL). Moreover, the company has an active scientific collaboration with Dr Janet Wilson (Consultant in Sexual Health at NHS Leeds) and Dr Emily Lord (Consultant in Genitourinary Medicine at NHS Oxfordshire Sexual Health Service) for the clinical testing of DuoBalanceTM ..

What products is BiotaLife developing?
BiotaLife is launching BloomCalma™ in November 2026, a pH-balanced microbiome-friendly intimate moisturising gel for external use during pregnancy and postpartum (https://www.biotalife.com/pages/products). It is also developing DuoBalance™, a patented, antibiotic-free and acid-free candidate medical device treating bacterial vaginosis (BV) and vaginal thrush, which is now advancing into clinical trials in collaboration with NHS Oxford and NHS Leeds.


Back to blog